Dr. Paul Thomas Targeted By Medical Board & Media After Landmark Vaccine Study

Recently, a landmark study was conducted by Dr. James Lyons-Weiler and Dr. Paul Thomas. The study compared vaccinated children and unvaccinated children and was published in the International Journal of Environmental Research and Public Health on November 22, 2020 after being peer reviewed.

Dr. Weiler, a research scientist and co-author of the study, was recently interviewed by Activist Post Contributor Spiro Skouras. In the interview, Weiler breaks down the data from the study which indicates children who were vaccinated showed a higher rate of medical office visits and experienced an elevated rate of medical symptoms ranging from Asthma and behavioral issues, to ADHD and Anemia.

Keep reading

The poison found in everyone, even unborn babies – and who is responsible for it

Imagine that a small group of people coordinated the intentional manufacture and release of a lethal poison – and imagine they knew this poison had special properties that meant, once released into the world, it would be inevitable that it would make its way into the blood of virtually every person on the planet, even babies in their mother’s womb, and stay there, like a ticking time bomb.

Well, that “ticking time bomb” waiting to explode into serious, even fatal, disease is not a fictional device from some doomsday thriller; it is real, it is inside virtually all of us, right now. Tick, tick, tick.

And we know exactly who is responsible. For a long time, powerful corporate interests succeeded in keeping this heinous, brazen, and ongoing public health threat hidden from regulators, from scientists, and from the public. But it is now a matter of public record that these people knew the potential for harm and grave threat to human life, and continued anyway.

The only reason the world knows anything about this today is because, in 1998, Earl Tennant, a courageous farmer from West Virginia, came to me demanding answers. His cattle were dying in droves and he was certain the trouble stemmed from the white foaming crud defiling his creek where his cattle drank. Something was efficiently killing off not only his cattle but also the deer and other wildlife. Earl wanted answers and I wanted to help him. Neither of us could have fathomed just how bad or how deep this really went.

Getting the answers required over two decades of litigation, continuing to this day. But like the cattle and other animals on his farm, Earl would not survive long enough to get all his answers. The dark secrets deliberately withheld from Earl about his creek and his dying cows, went far beyond his property line. The poison flowing into Earl’s creek was also leaching into the drinking water of 70,000 of his neighbors, but no one was being told a thing. And this was just the tip of the iceberg. In secret, the poison had in fact streamed all across the country, and into the bloodstreams of virtually every American.

Keep reading

Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.

“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”WATCH NOWVIDEO01:37Biotech shares soar on dealmaking, drug progress

Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.

“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”

The analyst didn’t immediately respond to a request for comment.

Keep reading